Topotarget A/S of Denmark has announced plans to reduce its staff and stop development of early compounds in order to focus its resources on belinostat, its late-stage histone deacetylase (HDAC) inhibitor for peripheral T-cell lymphoma. ---Subscribe to MedNous to access this article--- Company News
